FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2153443504> ?p ?o ?g. }

• W2153443504 endingPage "219" @default.
• W2153443504 startingPage "209" @default.
• W2153443504 abstract "Introduction: Studies have shown that ticagrelor has a further adenosine-mediated mechanism of action in addition to its potent inhibition of the P2Y 12 receptor, which may explain some of ticagrelor’s clinical characteristics. This study aimed to further characterize the adenosine pharmacology of ticagrelor, its major metabolites, and other P2Y 12 receptor antagonists. Methods: Inhibition of nucleoside transporter-mediated [ 3 H]adenosine uptake by ticagrelor, its major metabolites, and alternative P2Y 12 antagonists was examined in recombinant Madin-Darby canine kidney (MDCK) cells. The pharmacology of ticagrelor and its major metabolites at adenosine A 1 , A 2A , A 2B , and A 3 receptor subtypes was examined using in vitro radioligand binding and functional assays and ex vivo C-fiber experiments in rat and guinea pig vagus nerves. Results: Ticagrelor (and less effectively its metabolites) and the main cangrelor metabolite inhibited [ 3 H]adenosine uptake in equilibrative nucleoside transporter (ENT) 1-expressing MDCK cells, whereas cangrelor and the active metabolites of prasugrel or clopidogrel had no effect. No significant inhibitory activity was observed in MDCK cells expressing ENT2 or concentrative nucleoside transporters 2/3. Ticagrelor demonstrated high affinity (inhibition constant [K i ] = 41 nmol/L) for ENT1. In adenosine receptor-binding experiments, ticagrelor and its major circulating metabolite, AR-C124910XX, had low affinity (K i > 6 µmol/L) for each of the adenosine A 1 , A 2A , and A 2B receptors, whereas ticagrelor had a submicromolar (K i = 190 nmol/L) affinity for the adenosine A 3 receptor. However, in functional assays, at high concentrations (10 µmol/L) ticagrelor only partially inhibited 3 mmol/L adenosine-induced depolarizations in the guinea pig and rat vagus nerve preparations (by 35% and 49%, respectively). Conclusions: Ticagrelor inhibits cellular adenosine uptake selectively via ENT1 inhibition at concentrations of clinical relevance. However, the low-binding affinity and functional inhibition of adenosine receptors observed with ticagrelor or its metabolites indicate that they possess a negligible adenosine-like activity at clinically relevant concentrations." @default.
• W2153443504 created "2016-06-24" @default.
• W2153443504 creator A5000090567 @default.
• W2153443504 creator A5021704830 @default.
• W2153443504 creator A5050771546 @default.
• W2153443504 creator A5070973655 @default.
• W2153443504 creator A5076128057 @default.
• W2153443504 creator A5087121124 @default.
• W2153443504 date "2014-01-10" @default.
• W2153443504 modified "2023-10-14" @default.
• W2153443504 title "Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1" @default.
• W2153443504 cites W1493618786 @default.
• W2153443504 cites W158289124 @default.
• W2153443504 cites W1594729601 @default.
• W2153443504 cites W1882332667 @default.
• W2153443504 cites W1967690118 @default.
• W2153443504 cites W1970487416 @default.
• W2153443504 cites W1973985383 @default.
• W2153443504 cites W2007957848 @default.
• W2153443504 cites W2015170280 @default.
• W2153443504 cites W2041292257 @default.
• W2153443504 cites W2045883267 @default.
• W2153443504 cites W2054906104 @default.
• W2153443504 cites W2059673054 @default.
• W2153443504 cites W2064667702 @default.
• W2153443504 cites W2069561061 @default.
• W2153443504 cites W2071686230 @default.
• W2153443504 cites W2072536636 @default.
• W2153443504 cites W2073399805 @default.
• W2153443504 cites W2074631079 @default.
• W2153443504 cites W2083488580 @default.
• W2153443504 cites W2087465863 @default.
• W2153443504 cites W2103511697 @default.
• W2153443504 cites W2136228924 @default.
• W2153443504 cites W2140363256 @default.
• W2153443504 cites W2140501627 @default.
• W2153443504 cites W2144128379 @default.
• W2153443504 cites W2150655309 @default.
• W2153443504 cites W2160678403 @default.
• W2153443504 cites W2163050713 @default.
• W2153443504 cites W2165356900 @default.
• W2153443504 cites W2169920833 @default.
• W2153443504 cites W2171217147 @default.
• W2153443504 doi "https://doi.org/10.1177/1074248413511693" @default.
• W2153443504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24414167" @default.
• W2153443504 hasPublicationYear "2014" @default.
• W2153443504 type Work @default.
• W2153443504 sameAs 2153443504 @default.
• W2153443504 citedByCount "204" @default.
• W2153443504 countsByYear W21534435042014 @default.
• W2153443504 countsByYear W21534435042015 @default.
• W2153443504 countsByYear W21534435042016 @default.
• W2153443504 countsByYear W21534435042017 @default.
• W2153443504 countsByYear W21534435042018 @default.
• W2153443504 countsByYear W21534435042019 @default.
• W2153443504 countsByYear W21534435042020 @default.
• W2153443504 countsByYear W21534435042021 @default.
• W2153443504 countsByYear W21534435042022 @default.
• W2153443504 countsByYear W21534435042023 @default.
• W2153443504 crossrefType "journal-article" @default.
• W2153443504 hasAuthorship W2153443504A5000090567 @default.
• W2153443504 hasAuthorship W2153443504A5021704830 @default.
• W2153443504 hasAuthorship W2153443504A5050771546 @default.
• W2153443504 hasAuthorship W2153443504A5070973655 @default.
• W2153443504 hasAuthorship W2153443504A5076128057 @default.
• W2153443504 hasAuthorship W2153443504A5087121124 @default.
• W2153443504 hasConcept C104317684 @default.
• W2153443504 hasConcept C149011108 @default.
• W2153443504 hasConcept C170493617 @default.
• W2153443504 hasConcept C185592680 @default.
• W2153443504 hasConcept C2776543447 @default.
• W2153443504 hasConcept C2776708134 @default.
• W2153443504 hasConcept C2776991684 @default.
• W2153443504 hasConcept C2777028646 @default.
• W2153443504 hasConcept C2777628954 @default.
• W2153443504 hasConcept C2777849778 @default.
• W2153443504 hasConcept C2778938600 @default.
• W2153443504 hasConcept C2780549722 @default.
• W2153443504 hasConcept C2780890252 @default.
• W2153443504 hasConcept C49059817 @default.
• W2153443504 hasConcept C55493867 @default.
• W2153443504 hasConcept C67907053 @default.
• W2153443504 hasConcept C71924100 @default.
• W2153443504 hasConcept C98274493 @default.
• W2153443504 hasConceptScore W2153443504C104317684 @default.
• W2153443504 hasConceptScore W2153443504C149011108 @default.
• W2153443504 hasConceptScore W2153443504C170493617 @default.
• W2153443504 hasConceptScore W2153443504C185592680 @default.
• W2153443504 hasConceptScore W2153443504C2776543447 @default.
• W2153443504 hasConceptScore W2153443504C2776708134 @default.
• W2153443504 hasConceptScore W2153443504C2776991684 @default.
• W2153443504 hasConceptScore W2153443504C2777028646 @default.
• W2153443504 hasConceptScore W2153443504C2777628954 @default.
• W2153443504 hasConceptScore W2153443504C2777849778 @default.
• W2153443504 hasConceptScore W2153443504C2778938600 @default.
• W2153443504 hasConceptScore W2153443504C2780549722 @default.
• W2153443504 hasConceptScore W2153443504C2780890252 @default.
• W2153443504 hasConceptScore W2153443504C49059817 @default.

• next